Please upgrade your browser.
Pazopanib (Votrient) appears to delay disease progression by 54% in patients with advanced renal cell carcinoma, according to a study by Italian researchers.
In this questionnaire, which is designed to take approximately 20-30 minutes, we will ask you questions about your cancer history, your employment history, and information about your job.
Blessed is a word with which Koons has more than a passing acquaintance. Diagnosed during the summer of 2007 with clear-cell renal carcinoma - a form of kidney cancer typically found in people over 40 who are heavy smokers, obese or have high blood pressure - Koons had successful surgery to remove the tumor and has since resumed her training regimen with the hope of qualifying for the 2012 London Olympics.
Detection Of Circulating Tumor Cells In Peripheral Blood Of Patients With Renal Cell Carcinoma Correlates With Prognosis
In our study, 233 peripheral blood samples from 154 renal cell carcinoma patients were investigated for the presence of CTCs.(1) Interestingly, the presence of CTCs in peripheral blood did not correlate with either tumor size or tumor grade as was also previously shown by other authors.(2, 3) But as expected, detection of CTCs was significantly correlated with the presence of lymph node metastases (p<0.001; chi2-test) and distant metastases (p=0.014; chi2-test). Furthermore, we could show for the first time that occurrence of CTCs (Cytokeratin 8/18 labeled) was significantly correlated with poor overall survival for renal cell carcinoma patients (RR=2.3; P=0.048; multivariate Cox's regression hazard model).
Bayer HealthCare und die Kidney Cancer Association (KCA) haben gemeinsam den europäischen Journalistenpreis Advances in Renal Cancer 2010 ausgeschrieben. Der Preis würdigt Arbeiten, in denen sich Journalisten kritisch und objektiv mit der Problematik des Nierenkrebses auseinandersetzen. Die Auszeichnung ist mit 7.500 Euro dotiert und berücksichtigt Veröffentlichungen aus den Bereichen Print, Hörfunk, Fernsehen und Film.
Some new cancer drugs have been deemed too expensive and not cost effective by the UK's National Institute for Clinical Excellence. In response, drug companies have created PASin which they offer discounts or rebates to the UK National Health Service (NHS), so that patients can access these drugs. For example, in some schemes the NHS will pay for the cost of the drug if the patient responds, while the drug company will pay for it if the patient does not respond. In the NHS, cancer medicines are supplied to patients in hospital provider trusts, who are then reimbursed for the cost of the medicine from the patient's local primary care trust (PCT).
Fargo-Moorhead area residents help family of kidney cancer patient.
This Wall Street Journal article is consistent with the recent experience of the Kidney Cancer Association, which recently took on the mission of the California Kidney Cancer Foundation, which disbanded due to financial hardship.
|Powered by NeonCRM|